- Procter & Gamble Co (NYSE:PG) reported second-quarter FY22 sales growth of 6.12% year-on-year, to $20.95 billion, beating the analyst consensus of $20.34 billion.
- Organic sales increased 6%, driven by a 3% increase in shipment volume, a 3% increase in pricing to help offset the significant commodity and other input cost increases.
- Sales in the beauty segment rose 3%, the Grooming segment expanded 4%, and Health Care jumped 8%.
- Adjusted EPS of $1.66 beat the analyst consensus of $1.65.
- Gross profit decreased 2% Y/Y to $10.3 billion. The reported gross margin decreased by 400 basis points to 49.1%.
- The operating margin contracted 250 basis points to 24.7%, while operating income for the quarter fell 4% to $5.2 billion.
- P&G held $11.54 billion in cash and equivalents as of December 31, 2021.
- “We delivered very strong top-line growth and made sequential progress on earnings in the face of significant cost headwinds,” said CEO Jon Moeller.
- Outlook: P&G raised FY22 all-in sales growth outlook to 3% – 4% (previously 2% – 4%).
- The company continues to expect FY22 core EPS growth of 3% – 6% versus FY21 Core EPS of $5.66.
- P&G also expects to pay over $8 billion in dividends and repurchase $9 billion – $10 billion of common shares in FY22.
- Price Action: PG shares are trading higher by 1.24% at $158.68 in premarket on the last check Wednesday.
UBS Maintains Buy on Align Tech, Lowers Price Target to $500
UBS analyst Kevin Caliendo maintains Align Tech (NASDAQ:ALGN) with a Buy and lowers the price target from $620 to $500.
